CMS Official Calls Medicare Price Negotiations An ‘Ongoing Conversation’
The US Centers for Medicare & Medicaid Services’ Vinod Mitta discussed the agency’s latest thinking on the implementation of Medicare drug price negotiations at the Financial Times Pharma Summit.
You may also be interested in...
Calculating a ‘fair price’ for new versions of already negotiated moiety is also one of several that CMS is requesting input on in its recently released initial guidance on the negotiation program.
Regulatory attorneys suggest different issues that might form the basis of manufacturer-sponsored litigation against the Centers for Medicare and Medicaid Services.
Scrip’s Joseph Haas and Jessica Merrill discuss the US FTC’s oversight of the Amgen/Horizon deal and what it might portend for biopharma M&A with Leerink Partners' Dan Lepanto and ZS partner Cody Powers.